معرفی
Paul Robinson is a Senior Postdoctoral Researcher at the University of Oxford's Radcliffe Department of Medicine (Cardiovascular Division), based at the British Heart Foundation Centre for Research Excellence Laboratories in the John Radcliffe Hospital. He operates within the Watkins Group (Inherited Heart Muscle Disease) and Redwood Group (Cardiac Contractility), focusing on translational cardiovascular research.
His academic foundation includes a BSc (Hons) in Medical Biochemistry from Royal Holloway College London and a DPhil in Clinical Medicine from Exeter College, Oxford. With over 20 years of specialized research experience, he bridges molecular mechanisms with clinical manifestations of cardiac disease.
Robinson's research centers on how genetic mutations in sarcomeric proteins cause hypertrophic (HCM) and dilated (DCM) cardiomyopathies. He employs recombinant protein systems, biophysical assays, and advanced cardiomyocyte models to investigate altered contractility, calcium handling dysregulation, and pathological signaling cascades. His work established critical links between myofilament calcium buffering defects and disease progression, revealing how thin filament mutations disrupt cellular homeostasis. Current efforts focus on developing genetically encoded calcium sensors and identifying therapeutic compounds to restore contractile balance.
His publication record (2007-2023) demonstrates consistent focus on molecular cardiomyopathy mechanisms, with recent work emphasizing calcium imaging innovations and mutation-specific pathophysiological pathways. Key studies revealed opposing effects of HCM/DCM mutations on calcium affinity and identified NFAT/Akt signaling activation as a consequence of contractile dysfunction.
As a core member of the CureHeart project—awarded the British Heart Foundation's £30 million Big Beat Challenge—Robinson contributes to developing gene-editing therapies for inherited cardiomyopathies. His laboratory work integrates with international collaborations featured in high-impact journals including Nature, Journal of Biological Chemistry, and American Journal of Physiology.
His research groups utilize cutting-edge facilities for protein biochemistry, cellular electrophysiology, and stem cell-derived cardiomyocyte models. Recent initiatives include CalTrack software for automated calcium transient analysis and investigations into paracrine signaling pathways in cardiac fibrosis, positioning his work at the frontier of precision cardiovascular medicine.
